Literature DB >> 15472207

Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay.

Alan L Schneyer1, Qifa Wang, Yisrael Sidis, Patrick M Sluss.   

Abstract

Follistatin (FST) is a monomeric activin-binding and neutralization protein that has at least three isoforms in human tissues and fluids. The full-length FS315 protein has an acidic 26-residue C-terminal tail that is not present in the shortest form, FS288, due to alternative splicing. An intermediate form, FS303, was identified in follicular fluid that is presumably derived by proteolytic processing of this tail domain. Interestingly, the biochemistry of each of these three isoforms is distinct, including their ability to bind to cell surface proteoglycans, an activity that ranks in the order FS288 > FS303 > FS315. This would suggest that the soluble, circulating FST isoform is likely to be FS315, a hypothesis supported by previous determinations that the serum and follicular fluid forms of FST are biochemically distinct. To test this hypothesis, we developed an immunoassay that is specific for full-length FS315. This assay was validated for use with human serum and follicular fluid samples and then used to examine FST in these fluid compartments. Our results indicate that FS315 is indeed the major circulating FST isoform but is undetectable in follicular fluid samples aspirated from normal women or women with polycystic ovary syndrome. These observations confirm the compartmentalization of FST isoforms according to their biochemical properties and biological actions so that the most soluble form is found in the circulation, whereas the forms that bind to cell surface proteoglycans are found in tissue compartments such as the ovarian follicle. They also confirm that the source of FST in human serum is not the ovarian follicle.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472207     DOI: 10.1210/jc.2004-0162

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  The influence of follistatin on mechanical properties of bone tissue in growing mice with overexpression of follistatin.

Authors:  Anna Gajos-Michniewicz; Elzbieta Pawlowska; Tomasz Ochedalski; Agnieszka Piastowska-Ciesielska
Journal:  J Bone Miner Metab       Date:  2012-02-07       Impact factor: 2.626

2.  FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.

Authors:  Abir Mukherjee; Yisrael Sidis; Amy Mahan; Michael J Raher; Yin Xia; Evan D Rosen; Kenneth D Bloch; Melissa K Thomas; Alan L Schneyer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

Review 3.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

Review 4.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

5.  Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.

Authors:  Janaiah Kota; Chalonda R Handy; Amanda M Haidet; Chrystal L Montgomery; Amy Eagle; Louise R Rodino-Klapac; Danielle Tucker; Christopher J Shilling; Walter R Therlfall; Christopher M Walker; Steven E Weisbrode; Paul M L Janssen; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar
Journal:  Sci Transl Med       Date:  2009-11-11       Impact factor: 17.956

6.  Imbalance of Amniotic Fluid Activin-A and Follistatin in Intraamniotic Infection, Inflammation, and Preterm Birth.

Authors:  John T Hardy; Irina A Buhimschi; Megan E McCarthy; Guomao Zhao; Christine A Laky; Lydia L Shook; Catalin S Buhimschi
Journal:  J Clin Endocrinol Metab       Date:  2016-05-09       Impact factor: 5.958

Review 7.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

Review 8.  The biology of activin: recent advances in structure, regulation and function.

Authors:  Yin Xia; Alan L Schneyer
Journal:  J Endocrinol       Date:  2009-03-09       Impact factor: 4.286

9.  The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.

Authors:  Robin Stamler; Henry T Keutmann; Yisrael Sidis; Chandramohan Kattamuri; Alan Schneyer; Thomas B Thompson
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

10.  Drosophila Follistatin exhibits unique structural modifications and interacts with several TGF-beta family members.

Authors:  Daniela Bickel; Ripal Shah; Scott C Gesualdi; Theodor E Haerry
Journal:  Mech Dev       Date:  2007-10-05       Impact factor: 1.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.